Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,098 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Clot Blood Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Improving Venous Thromboembolism Prophylaxis

NCT01304108
View directory record Official record
Conditions
Venous Thromboembolism, Delivery of Health Care, Quality Improvement
Interventions
VTE-P Tollgate, BLAZE Pop up, Usual Care
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
17 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 24, 2011 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Prophylactic Enoxaparin Dosing for Prevention of Venous Thromboembolism in Pregnancy.

NCT00878826
View directory record Official record
Conditions
Venous Thrombosis
Interventions
Enoxaparin
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 15, 2016 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational

Merci Registry - Real World Use of the Merci Retrieval System in Acute Ischemic Stroke

NCT00478478
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Mechanical Thrombectomy
Procedure
Lead sponsor
Stryker Neurovascular
Industry
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 9, 2014 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational

Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait

NCT04349189
View directory record Official record
Conditions
Sickle Cell Disease, Venous Thrombosis, Sickle Cell Trait, Hypercoagulable State, Venous Thromboembolism
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Withdrawn Not applicable Interventional

Post Thrombotic Syndrome Prevention Study

NCT03039517
View directory record Official record
Conditions
Post Thrombotic Syndrome, Deep Vein Thrombosis
Interventions
ACTitouch, Compression garments (stockings)
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 21, 2019 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 1 Interventional

Rivaroxaban Pharmacokinetics/Pharmacodynamics (PK/PD) Study in Pediatric Subjects

NCT01145859
View directory record Official record
Conditions
Venous Thrombosis, Pediatrics
Interventions
Rivaroxaban (Xarelto, BAY59-7939)
Drug
Lead sponsor
Bayer
Industry
Eligibility
6 Months to 18 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
16
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional

Clopidogrel Prevention of Early Arteriovenous (AV) Fistula Thrombosis

NCT03289520
View directory record Official record
Conditions
Kidney Failure, Hemodialysis Fistula Thrombosis
Interventions
Clopidogrel, Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
877 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
9
States / cities
Birmingham, Alabama • Iowa City, Iowa • Portland, Maine + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational

HTRS TE Registry (ThromboEmbolism Registry)

NCT00266994
View directory record Official record
Conditions
Thromboembolism
Interventions
Not listed
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
Not listed
Enrollment
2,760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 20, 2013 · Synced Sep 3, 2026, 9:47 AM EDT
Recruiting Phase 3 Interventional

Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable

NCT07430956
View directory record Official record
Conditions
Atrial Fibrillation (AF)
Interventions
REGN7508, REGN9933, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,628 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
18
States / cities
Dothan, Alabama • Fremont, California • Huntington Beach, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Phase 1 Interventional

Multiple-Dose Study Apixaban in Pediatric Subjects With an Indwelling Central Venous Catheter

NCT01195727
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Apixaban
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
12 Years to 17 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Orange, California • New Brunswick, New Jersey • Toledo, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Sep 3, 2026, 9:47 AM EDT
Not listed Not applicable Interventional

Modeling Genotype and Other Factors to Enhance the Safety of Coumadin Prescribing

NCT00484640
View directory record Official record
Conditions
Atrial Fibrillation, Deep Venous Thrombosis, Heart Valve Replacement, Pulmonary Embolism
Interventions
Coumadin
Drug
Lead sponsor
Agency for Healthcare Research and Quality (AHRQ)
Federal
Eligibility
40 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Madison, Wisconsin • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 10, 2007 · Synced Sep 3, 2026, 9:47 AM EDT
Recruiting Phase 2 Interventional

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus

NCT05969496
View directory record Official record
Conditions
Renal Cancer, Kidney Cancer, Renal Cell Carcinoma, Inferior Vena Cava Thrombosis
Interventions
Axitinib, Pembrolizumab
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
3
States / cities
Aurora, Colorado • Highlands Ranch, Colorado • Lone Tree, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fatty Acid Regulation of Platelet Function in Diabetes

NCT02373332
View directory record Official record
Conditions
Thrombosis, Type 2 Diabetes Mellitus
Interventions
omega-3 and -6 fatty acids and their 12-LOX oxylipins
Other
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
2
States / cities
Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2021 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2Phase 3 Interventional Results available

To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions

NCT00493064
View directory record Official record
Conditions
Retinal Vein Occlusion
Interventions
Nicotinic acid, Prednisolone acetate
Drug
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
Not listed
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Dec 20, 2018 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional Results available

Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Hip Replacement Surgery (ADVANCE-3)

NCT00423319
View directory record Official record
Conditions
Deep Vein Thrombosis, Pulmonary Embolism
Interventions
Enoxaparin, Apixaban, Enoxaparin-matching placebo, Apixaban-matching placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
5,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Sacramento, California + 12 more
Source: ClinicalTrials.gov public record
Updated May 13, 2014 · Synced Sep 3, 2026, 9:47 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Systematic Review and Meta-Analysis of Venous Thromboembolism (VTE) Risk Assessment in Hospitalized Medical Patients

NCT01446510
View directory record Official record
Conditions
Venous Thromboembolism
Interventions
Application of VTE Risk Assessment
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 3, 2026, 9:47 AM EDT
Enrolling by invitation Phase 2 Interventional

Intra-Arterial Tenecteplase Following Endovascular Thrombectomy for Large Vessel Occlusion Stroke

NCT06781385
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Intra-arterial Tenecteplase, Intra-arterial Saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 2 Interventional

Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic Sclerosis

NCT02228850
View directory record Official record
Conditions
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Interventions
Alprostadil, Placebo
Drug · Other
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Industry
Eligibility
18 Years to 79 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Encinitas, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2016 · Synced Sep 3, 2026, 9:47 AM EDT
Withdrawn Phase 4 Interventional

ATHERO: Advanced Technology Halting Early Re-Stenosis and Occlusion

NCT00407940
View directory record Official record
Conditions
Arterial Occlusive Disease, Intermittent Claudication
Interventions
Lower extremity Atherectomy and Cryoplasty
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Not applicable Interventional

Patient Education Bundle vs. Nurses Feedback and Coaching to Prevent Missed Doses of VTE Prophylaxis

NCT03367364
View directory record Official record
Conditions
Venous Thrombosis (Disorder)
Interventions
Patient education bundle (PEB),, Nurse feedback and coaching (NFC)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Sep 3, 2026, 9:47 AM EDT
Active, not recruiting Not applicable Interventional

The PEERLESS II Study

NCT06055920
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
FlowTriever System, Anticoagulation Agents
Device · Drug
Lead sponsor
Inari Medical
Industry
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
42
States / cities
Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 3, 2026, 9:47 AM EDT
Terminated Not applicable Interventional Results available

Use of Clearway™ Balloon vs. Mechanical Thrombectomy as Initial Treatment for Acute Limb Ischemia

NCT00869375
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
Endovascular peripheral intervention
Device
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 85 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 20, 2014 · Synced Sep 3, 2026, 9:47 AM EDT
Completed Phase 3 Interventional

Clarification of Optimal Anticoagulation Through Genetics

NCT00839657
View directory record Official record
Conditions
Stroke, Venous Thrombosis, Atrial Fibrillation, Atrial Flutter
Interventions
Genotype-guided dosing algorithm for warfarin, Clinical-guided dosing algorithm for warfarin
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
1,015 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
18
States / cities
Birmingham, Alabama • San Francisco, California • Gainesville, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2016 · Synced Sep 3, 2026, 9:47 AM EDT